Markets

Amgen will buy a blockbuster psoriasis drug for $13.4 billion — and it’s part of a plan to get Celgene’s mega-merger with Bristol-Myers Squibb approved

Amgen will buy Otezla, Celgene‘s flagship psoriasis drug, for $US13.4 billion – or about $US11.2 billion after future cash tax benefits. The deal sweetens Celgene’s case to antitrust officials as it seeks approval for a $US74 billion merger with Bristol-Myers Squibb, which was first announced in January 2019. Shares of […]
Amgen will buy a blockbuster psoriasis drug for $13.4 billion — and it’s part of a plan to get Celgene’s mega-merger with Bristol-Myers Squibb approved
Markets

Allergan just got one step closer to approval for its migraine drug — and it’s part of a wave of new treatments for the condition that affects 38 million Americans

There’s a race to bring new migraine treatments to the 38 million Americans who have them. On Tuesday, Botox-maker Allergan said that its version of the medication succeeded in a late-stage trial. Allergan plans to submit the drug for approval in 2019. The new drugs are used to either prevent […]
Allergan just got one step closer to approval for its migraine drug  —  and it’s part of a wave of new treatments for the condition that affects 38 million Americans